A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy

Trial Profile

A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Atrophic vaginitis
  • Focus Therapeutic Use
  • Sponsors Peptonic Medical
  • Most Recent Events

    • 21 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 17 May 2017 Results from the exploratory part of this trial (n = 41) published in a Peptonic Medical media release.
    • 16 May 2017 According to a Peptonic Medical Media Release, Primary efficacy endpoints of the first part of this study, were not met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top